BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10784433)

  • 1. In vitro cytotoxicity of cis[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)] platinum(II) suspended in lipiodol in rat hepatoma AH-109A cells and human tumor cell lines.
    Kishimoto S; Noguchi T; Yamaoka T; Fukushima S; Takeuchi Y
    Biol Pharm Bull; 2000 Apr; 23(4):487-91. PubMed ID: 10784433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro antitumor activity, intracellular accumulation, and DNA adduct formation of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)] platinum (II) suspended in lipiodol.
    Kishimoto S; Miyazawa K; Fukushima S; Takeuchi Y
    Jpn J Cancer Res; 2000 Jan; 91(1):99-104. PubMed ID: 10744050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro release of SM-11355, cis[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)] platinum(II) suspended in lipiodol.
    Kishimoto S; Noguchi T; Yamaoka T; Fukushima S; Takeuchi Y
    Biol Pharm Bull; 2000 May; 23(5):637-40. PubMed ID: 10823679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxicity of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)]-platinum (II) suspended in Lipiodol in a newly established cisplatin-resistant rat hepatoma cell line.
    Kishimoto S; Miyazawa K; Terakawa Y; Ashikari H; Ohtani A; Fukushima S; Takeuchi Y
    Jpn J Cancer Res; 2000 Dec; 91(12):1326-32. PubMed ID: 11123433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation between intracellular accumulation and cytotoxic activity of cis-[((1R, 2R)-1, 2-cyclohexanediamine-N, N')bis(myristato)]platinum(II) suspended in Lipiodol.
    Kishimoto S; Ohtani A; Fukuda H; Fukushima S; Takeuchi Y
    Biol Pharm Bull; 2003 May; 26(5):683-6. PubMed ID: 12736512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effects of a novel lipophilic platinum complex (SM-11355) against a slowly-growing rat hepatic tumor after intra-hepatic arterial administration.
    Kishimoto S; Noguchi T; Yamaoka T; Fukushima S; Takeuchi Y
    Biol Pharm Bull; 2000 Mar; 23(3):344-8. PubMed ID: 10726891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis.
    Hanada M; Baba A; Tsutsumishita Y; Noguchi T; Yamaoka T; Chiba N; Nishikaku F
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):473-83. PubMed ID: 19104812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term disposition of a novel lipophilic platinum complex SM-11355 in dog after intrahepatic arterial administration: highly sensitive detection of platinum and radioactivity.
    Shimakura J; Fujimoto K; Komuro S; Nakano M; Kanamaru H
    Xenobiotica; 2002 May; 32(5):399-409. PubMed ID: 12065062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).
    Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
    Anticancer Res; 1996; 16(1):251-6. PubMed ID: 8615617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of human hepatoma cells orthotopically implanted in nude rats.
    Hanada M; Baba A; Tsutsumishita Y; Noguchi T; Yamaoka T
    Cancer Sci; 2009 Jan; 100(1):189-94. PubMed ID: 19037997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin/lipiodol.
    Fujiyama S; Shibata J; Maeda S; Tanaka M; Noumaru S; Sato K; Tomita K
    Br J Cancer; 2003 Nov; 89(9):1614-9. PubMed ID: 14583758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of zinostatin stimalamer (YM881) in human hepatoma cell lines and VX2 liver tumor-bearing rabbits.
    Tanaka S; Fujihara A; Yamamoto M; Ida H; Ohmi Y; Kitazaki T; Kikuchi Y; Yoshida S; Okamiya H; Numasaki Y; Konno T
    Res Commun Mol Pathol Pharmacol; 1996 May; 92(2):155-63. PubMed ID: 8774069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heat enhances the cytotoxicity of cis-diamminedichloroplatinum(II) and its analogues cis-1,1-cyclobutane-dicarboxylato(2R)-2-methyl-1,4- butanediammineplatinum(II) and cis-diammine(glycolato)platinum in vitro.
    Takahashi I; Maehara Y; Kusumoto H; Kohnoe S; Sugimachi K
    Cancer Chemother Pharmacol; 1993; 33(1):31-5. PubMed ID: 8269586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new orally active antitumor 1R,2R-cyclohexanediamine-platinum(IV) complex: trans-(n-valerato)chloro(1R,2R-cyclohexanediamine) (oxalato)platinum(IV).
    Kizu R; Nakanishi T; Hayakawa K; Matsuzawa A; Eriguchi M; Takeda Y; Akiyama N; Tashiro T; Kidani Y
    Cancer Chemother Pharmacol; 1999; 43(2):97-105. PubMed ID: 9923814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxicity of platinum(IV) and platinum(II) complexes containing 1R,2R-cyclohexanediamine as a ligand.
    Yamashita T; Hirose J; Noji M; Saito R; Tomida H; Kidani Y
    Biol Pharm Bull; 1993 Oct; 16(10):1014-8. PubMed ID: 8287030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of exposure and infusion times on the cytotoxicity and pharmacokinetics of cis-malonato[(4R, 5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II) .
    Kim HT; Kim DK; Cho YB; Kim TS; Jung I; Kim KH; Heo DS; Bang YJ; Shin SG; Kim NK
    Cancer Chemother Pharmacol; 1998; 41(2):109-16. PubMed ID: 9443623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-tumor activity of zinostatin stimalamer (YM 881) examined by human hepatoma cells in vitro and VX2 liver tumor in vivo].
    Tanaka S; Fujihara A; Yamamoto M; Asano M; Ida H; Ohmi Y; Kitazaki T; Kikuchi Y; Yoshida S; Okamiya H
    Gan To Kagaku Ryoho; 1994 Feb; 21(2):219-26. PubMed ID: 8311492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An orally active antitumor cyclohexanediamine-Pt(IV) complex: trans,cis,cis-bis(n-valerato)(oxalato)(1R,2R-cyclohexane diamine)Pt(IV).
    Kizu R; Nakanishi T; Miyazaki M; Tashiro T; Noji M; Matsuzawa A; Eriguchi M; Takeda Y; Akiyama N; Kidani Y
    Anticancer Drugs; 1996 May; 7(3):248-56. PubMed ID: 8791997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
    Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular uptake of an antitumor-active azole-bridged dinuclear platinum(II) complex in cisplatin-resistant tumor cells.
    Kishimoto S; Yasuda M; Suzuki R; Fukushima S
    Biometals; 2016 Dec; 29(6):1075-1083. PubMed ID: 27787693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.